

Daniel Souery

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8825076/publications.pdf>

Version: 2024-02-01

166
papers

7,401
citations

57758

44
h-index

64796

79
g-index

188
all docs

188
docs citations

188
times ranked

7396
citing authors

#	ARTICLE	IF	CITATIONS
1	Identifying the Common Genetic Basis of Antidepressant Response. <i>Biological Psychiatry Global Open Science</i> , 2022, 2, 115-126.	2.2	31
2	Pregabalin augmentation of antidepressants in major depression - results from a European multicenter study. <i>Journal of Affective Disorders</i> , 2022, 296, 485-492.	4.1	3
3	A meta-analysis of polygenic risk scores for mood disorders, neuroticism, and schizophrenia in antidepressant response. <i>European Neuropsychopharmacology</i> , 2022, 55, 86-95.	0.7	19
4	Evidence on sociodemographic and clinical correlates of antidepressant combination or augmentation with second-generation antipsychotics in major depressive disorder. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2022, 114, 110480.	4.8	3
5	Social withdrawal as a trans-diagnostic predictor of short-term remission: a meta-analysis of five clinical cohorts. <i>International Clinical Psychopharmacology</i> , 2022, 37, 38-45.	1.7	9
6	The sociodemographic and clinical profile of patients with major depressive disorder receiving SSRIs as first-line antidepressant treatment in European countries. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2022, 272, 715-727.	3.2	14
7	Metabolizing status of CYP2C19 in response and side effects to medications for depression: Results from a naturalistic study. <i>European Neuropsychopharmacology</i> , 2022, 56, 100-111.	0.7	5
8	Polygenic risk scores for neuropsychiatric, inflammatory, and cardio-metabolic traits highlight possible genetic overlap with suicide attempt and treatment-emergent suicidal ideation. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2022, 189, 74-85.	1.7	8
9	The sociodemographic and clinical phenotype of European patients with major depressive disorder undergoing first-line antidepressant treatment with NaSSAs. <i>Journal of Affective Disorders</i> , 2022, 312, 225-234.	4.1	2
10	Practical recommendations for the management of treatment-resistant depression with esketamine nasal spray therapy: Basic science, evidence-based knowledge and expert guidance. <i>World Journal of Biological Psychiatry</i> , 2021, 22, 1-15.	2.6	38
11	Drug repositioning for treatment-resistant depression: Hypotheses from a pharmacogenomic study. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021, 104, 110050.	4.8	21
12	Cost-effectiveness of genetic and clinical predictors for choosing combined psychotherapy and pharmacotherapy in major depression. <i>Journal of Affective Disorders</i> , 2021, 279, 722-729.	4.1	7
13	Higher polygenic risk scores for schizophrenia may be suggestive of treatment non-response in major depressive disorder. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021, 108, 110170.	4.8	36
14	Possible Modulatory Role of ARC Gene Variants in Mood Disorders. <i>Clinical Psychopharmacology and Neuroscience</i> , 2021, 19, 46-52.	2.0	2
15	The Role of Relationship Status in Major Depressive Disorder - Results of the European Group for the Study of Resistant Depression. <i>Journal of Affective Disorders</i> , 2021, 286, 149-157.	4.1	4
16	Sex-related effects in major depressive disorder: Results of the European Group for the Study of Resistant Depression. <i>Depression and Anxiety</i> , 2021, 38, 896-906.	4.1	18
17	A New Characterization of Mental Health Disorders Using Digital Behavioral Data: Evidence from Major Depressive Disorder. <i>Journal of Clinical Medicine</i> , 2021, 10, 3109.	2.4	6
18	Melancholic features in major depression – a European multicenter study. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021, 110, 110285.	4.8	17

#	ARTICLE	IF	CITATIONS
19	Research Domain Criteria (RDoC): A Perspective to Probe the Biological Background behind Treatment Efficacy in Depression. <i>Current Medicinal Chemistry</i> , 2021, 28, 4296-4320.	2.4	1
20	Combining psychopharmacotherapy and psychotherapy is not associated with better treatment outcome in major depressive disorder - evidence from the European Group for the Study of Resistant Depression. <i>Journal of Psychiatric Research</i> , 2021, 141, 167-175.	3.1	14
21	The Choice of either Quetiapine or Aripiprazole as Augmentation Treatment in a European Naturalistic Sample of Patients with Major Depressive Disorder. <i>International Journal of Neuropsychopharmacology</i> , 2021, , .	2.1	2
22	Methodology for clinical genotyping of CYP2D6 and CYP2C19. <i>Translational Psychiatry</i> , 2021, 11, 596.	4.8	15
23	Social dysfunction in mood disorders and schizophrenia: Clinical modulators in four independent samples. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2020, 99, 109835.	4.8	32
24	Add-on benzodiazepine treatment in patients with major depressive disorder – results from a European cross-sectional multicenter study. <i>European Neuropsychopharmacology</i> , 2020, 41, 70-80.	0.7	14
25	P.179 Polygenic risk scores for multiple psychiatric, inflammatory and cardio-metabolic traits highlight possible genetic overlap with suicide attempt. <i>European Neuropsychopharmacology</i> , 2020, 40, S105-S106.	0.7	0
26	Clinical Correlates and Outcome of Major Depressive Disorder and Comorbid Migraine: A Report of the European Group for the Study of Resistant Depression. <i>International Journal of Neuropsychopharmacology</i> , 2020, 23, 571-577.	2.1	5
27	CYP2D6 Revisited in GENDEP: Inter-Platform Concordance. <i>Biological Psychiatry</i> , 2020, 87, S148.	1.3	0
28	A polygenic predictor of treatment-resistant depression using whole exome sequencing and genome-wide genotyping. <i>Translational Psychiatry</i> , 2020, 10, 50.	4.8	33
29	Genetic variants associated with psychotic symptoms across psychiatric disorders. <i>Neuroscience Letters</i> , 2020, 720, 134754.	2.1	9
30	Results of the European Group for the Study of Resistant Depression (GSRD) – basis for further research and clinical practice. <i>World Journal of Biological Psychiatry</i> , 2019, 20, 427-448.	2.6	89
31	F105AN EXOME SEQUENCING STUDY IN TREATMENT-RESISTANT DEPRESSION. <i>European Neuropsychopharmacology</i> , 2019, 29, S1166-S1167.	0.7	0
32	F93. CYP2D6 Revisited in GENDEP, a Multicenter Clinical Trial of Nortriptyline and Escitalopram. <i>Biological Psychiatry</i> , 2019, 85, S248-S249.	1.3	0
33	High occupational level is associated with poor response to the treatment of depression: A replication study. <i>European Neuropsychopharmacology</i> , 2019, 29, 349-355.	0.7	3
34	Effect of antidepressant switching between nortriptyline and escitalopram after a failed first antidepressant treatment among patients with major depressive disorder. <i>British Journal of Psychiatry</i> , 2019, 215, 494-501.	2.8	10
35	WHOLE EXOME SEQUENCING REVEALS RISK FACTORS IN TREATMENT RESISTANT DEPRESSION. <i>European Neuropsychopharmacology</i> , 2019, 29, S934-S935.	0.7	0
36	Major Depression and Comorbid Diabetes - Findings from the European Group for the Study of Resistant Depression. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2019, 94, 109638.	4.8	20

#	ARTICLE	IF	CITATIONS
37	Comorbid hypertension in patients with major depressive disorder “ Results from a European multicenter study. <i>European Neuropsychopharmacology</i> , 2019, 29, 777-785.	0.7	18
38	Temperament and character influence on depression treatment outcome. <i>Journal of Affective Disorders</i> , 2019, 252, 464-474.	4.1	27
39	Predominant polarity in bipolar disorder patients: The COPE bipolar sample. <i>Journal of Affective Disorders</i> , 2019, 250, 43-50.	4.1	17
40	Trajectories of Suicidal Ideation During 12 Weeks of Escitalopram or Nortriptyline Antidepressant Treatment Among 811 Patients With Major Depressive Disorder. <i>Journal of Clinical Psychiatry</i> , 2019, 80, .	2.2	7
41	M74 HIGHER POLYGENIC RISK SCORES FOR SCHIZOPHRENIA MAY BE SUGGESTIVE OF NON-RESPONSE TO DRUGS FOR DEPRESSION IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER. <i>European Neuropsychopharmacology</i> , 2019, 29, S206-S207.	0.7	0
42	Attrition in treatment-resistant depression. <i>International Clinical Psychopharmacology</i> , 2019, 34, 161-169.	1.7	0
43	Genome-wide association study of treatment-resistance in depression and meta-analysis of three independent samples. <i>British Journal of Psychiatry</i> , 2019, 214, 36-41.	2.8	44
44	Opinion paper: poor response to treatment of depression in people in high occupational levels. <i>Psychological Medicine</i> , 2019, 49, 49-54.	4.5	8
45	Clinical factors predicting treatment resistant depression: affirmative results from the European multicenter study. <i>Acta Psychiatrica Scandinavica</i> , 2019, 139, 78-88.	4.5	92
46	The Genetics of Treatment-Resistant Depression: A Critical Review and Future Perspectives. <i>International Journal of Neuropsychopharmacology</i> , 2019, 22, 93-104.	2.1	32
47	Psychotic Features in Patients With Major Depressive Disorder. <i>Journal of Clinical Psychiatry</i> , 2019, 80, .	2.2	28
48	Major Depression and the Degree of Suicidality: Results of the European Group for the Study of Resistant Depression (GSRD). <i>International Journal of Neuropsychopharmacology</i> , 2018, 21, 539-549.	2.1	54
49	Clinical correlates of augmentation/combination treatment strategies in major depressive disorder. <i>Acta Psychiatrica Scandinavica</i> , 2018, 137, 401-412.	4.5	37
50	Antidepressant drug-specific prediction of depression treatment outcomes from genetic and clinical variables. <i>Scientific Reports</i> , 2018, 8, 5530.	3.3	51
51	Comorbid thyroid disease in patients with major depressive disorder - results from the European Group for the Study of Resistant Depression (GSRD). <i>European Neuropsychopharmacology</i> , 2018, 28, 752-760.	0.7	47
52	Low comorbid obsessive-compulsive disorder in patients with major depressive disorder “ Findings from a European multicenter study. <i>Journal of Affective Disorders</i> , 2018, 227, 254-259.	4.1	6
53	Pleiotropic genes in psychiatry: Calcium channels and the stress-related FKBP5 gene in antidepressant resistance. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2018, 81, 203-210.	4.8	31
54	Early improvement and response to antidepressant medications in adults with major depressive disorder. Meta-analysis and study of a sample with treatment-resistant depression. <i>Journal of Affective Disorders</i> , 2018, 227, 777-786.	4.1	32

#	ARTICLE	IF	CITATIONS
55	The serotonin transporter and the activity regulated cytoskeleton-associated protein genes in antidepressant response and resistance: $5-HTTLPR$ and other variants. Human Psychopharmacology, 2018, 33, e2682.	1.5	7
56	Clinical factors associated with augmentation treatment with second-generation antipsychotics and lithium in major depression – Results from a European multicenter study. European Neuropsychopharmacology, 2018, 28, 1305-1313.	0.7	15
57	Effect of cytochrome CYP2C19 metabolizing activity on antidepressant response and side effects: Meta-analysis of data from genome-wide association studies. European Neuropsychopharmacology, 2018, 28, 945-954.	0.7	64
58	Genes associated with anhedonia: a new analysis in a large clinical trial (GENDEP). Translational Psychiatry, 2018, 8, 150.	4.8	19
59	Refining Prediction in Treatment-Resistant Depression. Journal of Clinical Psychiatry, 2018, 79, 16m11385.	2.2	76
60	Clinical characteristics and treatment outcomes of patients with major depressive disorder and comorbid anxiety disorders - results from a European multicenter study. Journal of Psychiatric Research, 2017, 91, 1-13.	3.1	77
61	Pharmacogenetics of antidepressant response: A polygenic approach. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2017, 75, 128-134.	4.8	71
62	Association between C-reactive protein (CRP) with depression symptom severity and specific depressive symptoms in major depression. Brain, Behavior, and Immunity, 2017, 62, 344-350.	4.1	202
63	Neuroplasticity and second messenger pathways in antidepressant efficacy: pharmacogenetic results from a prospective trial investigating treatment resistance. European Archives of Psychiatry and Clinical Neuroscience, 2017, 267, 723-735.	3.2	21
64	The impact of comorbid post-traumatic stress disorder in patients with major depressive disorder on clinical features, pharmacological treatment strategies, and treatment outcomes – Results from a cross-sectional European multicenter study. European Neuropsychopharmacology, 2017, 27, 625-632.	0.7	19
65	The Impact of BDNF Polymorphisms on Suicidality in Treatment-Resistant Major Depressive Disorder: A European Multicenter Study. International Journal of Neuropsychopharmacology, 2017, 20, 782-787.	2.1	10
66	Prescribing patterns of psychiatric drugs in major depressive disorder – Findings from a large European multicenter, cross-sectional study. European Psychiatry, 2017, 41, S367-S367.	0.2	0
67	A New Prediction Model for Evaluating Treatment-Resistant Depression. Journal of Clinical Psychiatry, 2017, 78, 215-222.	2.2	73
68	The impact of serotonin receptor 1A and 2A gene polymorphisms and interactions on suicide attempt and suicide risk in depressed patients with insufficient response to treatment – a European multicentre study. International Clinical Psychopharmacology, 2016, 31, 1-7.	1.7	19
69	Combining clinical variables to optimize prediction of antidepressant treatment outcomes. Journal of Psychiatric Research, 2016, 78, 94-102.	3.1	149
70	High occupational level is associated with poor response to treatment of depression. European Neuropsychopharmacology, 2016, 26, 1320-1326.	0.7	8
71	Pharmacological treatment strategies in unipolar depression in European tertiary psychiatric treatment centers – A pharmacoepidemiological cross-sectional multicenter study. European Neuropsychopharmacology, 2016, 26, 1960-1971.	0.7	50
72	Bipolar II disorder as a risk factor for postpartum depression. Journal of Affective Disorders, 2016, 204, 54-58.	4.1	30

#	ARTICLE	IF	CITATIONS
73	Clinical and genetic factors associated with suicide in mood disorder patients. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2016, 266, 181-193.	3.2	32
74	Transcriptomics and the mechanisms of antidepressant efficacy. <i>European Neuropsychopharmacology</i> , 2016, 26, 105-112.	0.7	19
75	Socio-demographic and clinical predictors of treatment resistant depression: A prospective European multicenter study. <i>Journal of Affective Disorders</i> , 2016, 189, 224-232.	4.1	73
76	Exploring the role of drug-metabolising enzymes in antidepressant side effects. <i>Psychopharmacology</i> , 2015, 232, 2609-2617.	3.1	31
77	Temperament and character profiles in bipolar I, bipolar II and major depressive disorder: Impact over illness course, comorbidity pattern and psychopathological features of depression. <i>Journal of Affective Disorders</i> , 2015, 184, 51-59.	4.1	38
78	Genetics of psychotropic medication induced side effects in two independent samples of bipolar patients. <i>Journal of Neural Transmission</i> , 2015, 122, 43-58.	2.8	14
79	The combined effect of genetic polymorphisms and clinical parameters on treatment outcome in treatment-resistant depression. <i>European Neuropsychopharmacology</i> , 2015, 25, 441-453.	0.7	77
80	What to expect from a third step in treatment resistant depression: A prospective open study on escitalopram. <i>World Journal of Biological Psychiatry</i> , 2015, 16, 472-482.	2.6	15
81	Neuronal cell adhesion genes and antidepressant response in three independent samples. <i>Pharmacogenomics Journal</i> , 2015, 15, 538-548.	2.0	34
82	Association study of CREB1 polymorphisms and suicidality in MDD: results from a European multicenter study on treatment resistant depression. <i>International Journal of Neuroscience</i> , 2015, 125, 336-343.	1.6	7
83	Dimensions of Delusions in Major Depression: Socio-demographic and Clinical Correlates in an Unipolar-Bipolar Sample. <i>Clinical Psychopharmacology and Neuroscience</i> , 2015, 13, 48-52.	2.0	15
84	An Inflammatory Biomarker as a Differential Predictor of Outcome of Depression Treatment With Escitalopram and Nortriptyline. <i>American Journal of Psychiatry</i> , 2014, 171, 1278-1286.	7.2	336
85	Genetic predictors of antidepressant side effects: A grouped candidate gene approach in the Genome-Based Therapeutic Drugs for Depression (GENDEP) study. <i>Journal of Psychopharmacology</i> , 2014, 28, 142-150.	4.0	18
86	Genetic differences in cytochrome P450 enzymes and antidepressant treatment response. <i>Journal of Psychopharmacology</i> , 2014, 28, 133-141.	4.0	75
87	PPP3CC gene: a putative modulator of antidepressant response through the B-cell receptor signaling pathway. <i>Pharmacogenomics Journal</i> , 2014, 14, 463-472.	2.0	41
88	Family history of major depression and residual symptoms in responder and non-responder depressed patients. <i>Comprehensive Psychiatry</i> , 2014, 55, 51-55.	3.1	8
89	Mixed, melancholic, and anxious features in depression: a cross-sectional study of sociodemographic and clinical correlates. <i>Annals of Clinical Psychiatry</i> , 2014, 26, 243-53.	0.6	4
90	Evaluation of the role of MAPK1 and CREB1 polymorphisms on treatment resistance, response and remission in mood disorder patients. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2013, 44, 271-278.	4.8	38

#	ARTICLE	IF	CITATIONS
91	Influence of family history of major depression, bipolar disorder, and suicide on clinical features in patients with major depression and bipolar disorder. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2013, 263, 93-103.	3.2	24
92	Variation in the HTR1A and HTR2A genes and social adjustment in depressed patients. <i>Journal of Affective Disorders</i> , 2013, 150, 649-652.	4.1	14
93	The International Society for Bipolar Disorders (ISBD) Task Force Report on Antidepressant Use in Bipolar Disorders. <i>American Journal of Psychiatry</i> , 2013, 170, 1249-1262.	7.2	579
94	Physical co-morbidity among treatment resistant vs. treatment responsive patients with major depressive disorder. <i>European Neuropsychopharmacology</i> , 2013, 23, 895-901.	0.7	28
95	Social adjustment among treatment responder patients with mood disorders. <i>Journal of Affective Disorders</i> , 2013, 150, 961-966.	4.1	2
96	The impact of Cytochrome P450 CYP1A2, CYP2C9, CYP2C19 and CYP2D6 genes on suicide attempt and suicide risk—a European multicentre study on treatment-resistant major depressive disorder. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2013, 263, 385-391.	3.2	16
97	Side effects associated with psychotropic medications in patients with bipolar disorder: evidence from two independent samples. <i>Journal of Psychopharmacology</i> , 2013, 27, 616-628.	4.0	19
98	Common Genetic Variation and Antidepressant Efficacy in Major Depressive Disorder: A Meta-Analysis of Three Genome-Wide Pharmacogenetic Studies. <i>American Journal of Psychiatry</i> , 2013, 170, 207-217.	7.2	216
99	The Impact of Adverse Life Events on Clinical Features and Interaction with Gene Variants in Mood Disorder Patients. <i>Psychopathology</i> , 2013, 46, 384-389.	1.5	10
100	Treatment resistance in severe unipolar depression: no association with psychotic or melancholic features. <i>Annals of Clinical Psychiatry</i> , 2013, 25, 97-106.	0.6	5
101	Genetic Predictors of Response to Serotonergic and Noradrenergic Antidepressants in Major Depressive Disorder: A Genome-Wide Analysis of Individual-Level Data and a Meta-Analysis. <i>PLoS Medicine</i> , 2012, 9, e1001326.	8.4	110
102	Second generation antipsychotics in the treatment of bipolar depression: a systematic review and meta-analysis. <i>Journal of Psychopharmacology</i> , 2012, 26, 603-617.	4.0	81
103	Failure to Replicate Influence of GRIK4 and GNB3 Polymorphisms on Treatment Outcome in Major Depression. <i>Neuropsychobiology</i> , 2012, 65, 70-75.	1.9	22
104	The impact of COMT gene polymorphisms on suicidality in treatment resistant major depressive disorder — A European Multicenter Study. <i>European Neuropsychopharmacology</i> , 2012, 22, 259-266.	0.7	38
105	European Group for the Study of Resistant Depression (GSRD) — Where have we gone so far: Review of clinical and genetic findings. <i>European Neuropsychopharmacology</i> , 2012, 22, 453-468.	0.7	111
106	Influence of COX-2 and OXTR polymorphisms on treatment outcome in treatment resistant depression. <i>Neuroscience Letters</i> , 2012, 516, 85-88.	2.1	21
107	Depression across mood disorders: review and analysis in a clinical sample. <i>Comprehensive Psychiatry</i> , 2012, 53, 24-38.	3.1	34
108	Genetic aetiology of mood disorders. , 2012, , 650-658.		0

#	ARTICLE	IF	CITATIONS
109	Citalopram versus desipramine in treatment resistant depression: Effect of continuation or switching strategies. A randomized open study. World Journal of Biological Psychiatry, 2011, 12, 364-375.	2.6	40
110	FC04-06 - Candidate gene association study of suicidality in treatment resistant MDD. European Psychiatry, 2011, 26, 1833-1833.	0.2	0
111	COMT and age at onset in mood disorders: A replication and extension study. Neuroscience Letters, 2011, 498, 218-221.	2.1	32
112	No influence of PTGS2 polymorphisms on response and remission to antidepressants in major depression. Psychiatry Research, 2011, 188, 166-169.	3.3	10
113	Clinical and healthcare burden in patients with bipolar disorder. International Clinical Psychopharmacology, 2011, 26, e44.	1.7	0
114	Bipolar disorder therapy in daily clinical practice. International Clinical Psychopharmacology, 2011, 26, e44-e45.	1.7	0
115	Brain-derived neurotrophic factor gene polymorphisms. International Clinical Psychopharmacology, 2011, 26, 1-10.	1.7	67
116	Switching Antidepressant Class Does Not Improve Response or Remission in Treatment-Resistant Depression. Journal of Clinical Psychopharmacology, 2011, 31, 512-516.	1.4	83
117	A preliminary investigation of the influence of CREB1 gene on treatment resistance in major depression. Journal of Affective Disorders, 2011, 128, 56-63.	4.1	45
118	Melancholic, atypical and anxious depression subtypes and outcome of treatment with escitalopram and nortriptyline. Journal of Affective Disorders, 2011, 132, 112-120.	4.1	93
119	Phenomenology of psychotic mood disorders: Lifetime and major depressive episode features. Journal of Affective Disorders, 2011, 135, 241-250.	4.1	29
120	Sexual dysfunction during treatment with serotonergic and noradrenergic antidepressants: Clinical description and the role of the 5-HTTLPR. World Journal of Biological Psychiatry, 2011, 12, 528-538.	2.6	31
121	Identification of clinical factors associated with resistance to antidepressants in bipolar depression: results from an European Multicentre Study. International Clinical Psychopharmacology, 2010, 25, 297-301.	1.7	18
122	5HT1A and 5HT2A receptor genes in treatment response phenotypes in major depressive disorder. International Clinical Psychopharmacology, 2010, 25, 228-231.	1.7	37
123	The impact of catechol-O-methyltransferase SNPs and haplotypes on treatment response phenotypes in major depressive disorder: a case-control association study. International Clinical Psychopharmacology, 2010, 25, 218-227.	1.7	51
124	Genome-Wide Pharmacogenetics of Antidepressant Response in the GENDEP Project. American Journal of Psychiatry, 2010, 167, 555-564.	7.2	314
125	Adverse reactions to antidepressants. British Journal of Psychiatry, 2009, 195, 202-210.	2.8	205
126	Moderation of antidepressant response by the serotonin transporter gene. British Journal of Psychiatry, 2009, 195, 30-38.	2.8	143

#	ARTICLE	IF	CITATIONS
127	Body weight as a predictor of antidepressant efficacy in the GENDEP project. <i>Journal of Affective Disorders</i> , 2009, 118, 147-154.	4.1	89
128	Genetic predictors of response to antidepressants in the GENDEP project. <i>Pharmacogenomics Journal</i> , 2009, 9, 225-233.	2.0	188
129	Cytochrome P450 CYP1A2, CYP2C9, CYP2C19 and CYP2D6 genes are not associated with response and remission in a sample of depressive patients. <i>International Clinical Psychopharmacology</i> , 2009, 24, 250-256.	1.7	69
130	Differential efficacy of escitalopram and nortriptyline on dimensional measures of depression. <i>British Journal of Psychiatry</i> , 2009, 194, 252-259.	2.8	170
131	Dissociation in Major Depressive Disorder: A Pilot Study. <i>Journal of Trauma and Dissociation</i> , 2008, 9, 411-421.	1.9	22
132	Current issues in bipolar disorder: A critical review. <i>European Neuropsychopharmacology</i> , 2007, 17, 687-695.	0.7	56
133	Clinical Factors Associated With Treatment Resistance in Major Depressive Disorder. <i>Journal of Clinical Psychiatry</i> , 2007, 68, 1062-1070.	2.2	407
134	Shortened onset of action of antidepressants in major depression using acetylsalicylic acid augmentation: a pilot open-label study. <i>International Clinical Psychopharmacology</i> , 2006, 21, 227-231.	1.7	199
135	Role of risperidone in the treatment of bipolar disorder. <i>Future Neurology</i> , 2006, 1, 535-543.	0.5	0
136	Pharmacogenetics of bipolar disorders. , 2006, , 75-100.		0
137	Treatment-resistant depression. <i>Journal of Clinical Psychiatry</i> , 2006, 67 Suppl 6, 16-22.	2.2	83
138	Treatment-Resistant Mood Disorders: From Diagnosis to Treatment. , 2005, , 373-401.		0
139	Serotonin transporter 5HTTLPR polymorphism and affective disorders: no evidence of association in a large European multicenter study. <i>European Journal of Human Genetics</i> , 2004, 12, 377-382.	2.8	78
140	Non-replication of the brain-derived neurotrophic factor (BDNF) association in bipolar affective disorder: A Belgian patient-control study. <i>American Journal of Medical Genetics Part A</i> , 2004, 129B, 34-35.	2.4	62
141	Molecular genetics of affective disorders. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2004, 28, 865-877.	4.8	9
142	The Multiple Facets of Treatment-Resistant Depression. <i>CNS Spectrums</i> , 2004, 9, 803-807.	1.2	10
143	Molecular genetics in the analysis of suicide. <i>Annals of Medicine</i> , 2003, 35, 191-196.	3.8	28
144	Lack of association between the 5HT2A receptor polymorphism (T102C) and unipolar affective disorder in a multicentric European study. <i>European Neuropsychopharmacology</i> , 2003, 13, 365-368.	0.7	20

#	ARTICLE	IF	CITATIONS
145	Molecular genetics of affective disorders. International Journal of Neuropsychopharmacology, 2003, 6, 155-169.	2.1	7
146	Molecular genetics of affective disorders. Current Opinion in Psychiatry, 2003, 16, S63-S70.	6.3	1
147	Fluvoxamine-induced hyperglycaemia in a diabetic patient with comorbid depression. International Journal of Neuropsychopharmacology, 2003, 6, 85-87.	2.1	9
148	Introduction to the Special Section New advances in the understanding and treatment of bipolar disorder. International Journal of Neuropsychopharmacology, 2003, 6, 123-125.	2.1	2
149	Positive association of dopamine D2 receptor polymorphism with bipolar affective disorder in a European multicenter association study of affective disorders. American Journal of Medical Genetics Part A, 2002, 114, 177-185.	2.4	50
150	Tryptophan hydroxylase polymorphism and suicidality in unipolar and bipolar affective disorders: a multicenter association study. Biological Psychiatry, 2001, 49, 405-409.	1.3	66
151	The characterization and definition of treatment-resistant mood disorders. , 2001, , 3-29.		13
152	Interactions desÂgÃˆnes et de l'environnement dans les troubles duÂcomportement. Cahiers De Psychologie Clinique, 2001, nÂ° 16, 25-32.	0.1	0
153	A European multicenter association study ofHTR2A receptor polymorphism in bipolar affective disorder. , 2000, 96, 136-140.		38
154	No evidence for the involvement of CAG/CTG repeats from within 18q21.33â€“q23 in bipolar disorder. European Journal of Human Genetics, 2000, 8, 385-388.	2.8	8
155	A European multicenter association study of HTR2A receptor polymorphism in bipolar affective disorder. American Journal of Medical Genetics Part A, 2000, 96, 136-140.	2.4	2
156	Genetic refinement and physical mapping of a chromosome 18q candidate region for bipolar disorder. European Journal of Human Genetics, 1999, 7, 427-434.	2.8	19
157	Short-term and long-term treatment for bipolar patients: beyond the guidelines. Journal of Affective Disorders, 1999, 55, 79-85.	4.1	17
158	Social adjustment and self-esteem in remitted patients with unipolar and bipolar affective disorder: A case-control study. Comprehensive Psychiatry, 1999, 40, 24-30.	3.1	49
159	Molecular Interpretation of Expanded RED Products in Bipolar Disorder by CAG/CTG Repeats Located at Chromosomes 17q and 18q. Neurobiology of Disease, 1999, 6, 424-432.	4.4	27
160	Definition criteria for treatment resistant depression. European Psychiatry, 1998, 13, 206S-206S.	0.2	0
161	Compliance and therapeutic issues in resistant depression. International Clinical Psychopharmacology, 1998, 13, S13-S18.	1.7	15
162	Expanded trinucleotide CAG repeats in families with bipolar affective disorder. Biological Psychiatry, 1997, 42, 1115-1122.	1.3	53

#	ARTICLE	IF	CITATIONS
163	No association between bipolar affective disorder and a serotonin receptor (5-HT2A) polymorphism. Psychiatry Research, 1997, 70, 65-69.	3.3	44
164	Linkage analysis of families with bipolar illness and chromosome 18 markers. Biological Psychiatry, 1996, 39, 679-688.	1.3	73
165	Association study of bipolar disorder with candidate genes involved in catecholamine neurotransmission: DRD2, DRD3, DAT1, and TH genes. , 1996, 67, 551-555.		67
166	Pharmacogenetics of Bipolar Disorder. , 0, , 75-100.		0